​

Spyre Therapeutics Ownership | Who Owns Spyre Therapeutics?

OverviewForecastRevenueFinancialsChart

Spyre Therapeutics Ownership Summary

Spyre Therapeutics is owned by 7.08% institutional investors, 5.90% insiders, and 87.02% retail investors. Vanguard group is the largest institutional shareholder, holding 5.39% of SYRE shares. Fidelity Growth Compy Commingled Pl S is the top mutual fund, with 3.66% of its assets in Spyre Therapeutics shares.

SYRE Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockSpyre Therapeutics7.08%5.90%87.02%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.75%11.83%52.41%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Vanguard group4.04M5.39%$132.19M
Fmr11.78M3.40%$594.23M
Blackrock funding, inc. /de5.52M1.60%$278.49M
Boxer capital696.48K1.54%$20.48M
Rtw investments, lp4.17M1.21%$210.44M
Fairmount funds management4.02M1.16%$202.67M
Perceptive advisors3.78M1.09%$190.83M
Vr adviser3.69M1.06%$185.89M
Driehaus capital management2.79M0.81%$140.77M
State street2.61M0.75%$131.50M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Fairmount funds management4.02M14.64%$202.67M
Vr adviser3.69M6.94%$185.89M
Commodore capital lp1.91M5.58%$96.46M
Tang capital management1.89M4.85%$95.44M
B group100.00K3.74%$5.04M
Perceptive advisors3.78M3.73%$190.83M
Affinity asset advisors1.28M3.33%$64.52M
Caligan partners lp878.13K2.95%$44.29M
Tcg crossover management1.90M2.74%$95.87M
Rtw investments, lp4.17M2.09%$210.44M

Top Buyers

HolderShares% AssetsChange
Vanguard group4.04M0.00%984.34K
Jpmorgan chase979.30K0.00%916.35K
Caligan partners lp878.13K2.95%878.13K
Perceptive advisors3.78M3.73%714.00K
Paradigm biocapital advisors lp1.96M2.02%490.00K

Top Sellers

HolderShares% AssetsChange
Capital investors1.75M0.02%-1.75M
Jefferies financial group---1.39M
Deerfield management company, l.p. (series c)---710.63K
Braidwell lp932.82K1.57%-701.79K
Farallon capital management---666.00K

New Positions

HolderShares% AssetsChangeValue
Caligan partners lp878.13K2.95%878.13K$44.29M
Vanguard fiduciary trust464.65K0.01%464.65K$23.44M
Samlyn capital396.66K0.34%396.66K$20.01M
Boothbay fund management193.03K0.13%193.03K$9.74M
First trust advisors lp178.39K0.01%178.39K$9.00M

Sold Out

HolderChange
National bank of canada /fi/-1.00
Amundi-5.00
Pacific capital wealth advisors-8.00
True wealth design-16.00
Lindbrook capital-19.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 2026116-25.64%24,505,642-69.74%70.06%75-29.91%283.70%
Dec 31, 2025114-17.39%40,966,319-36.29%540.74%7919.70%18-59.09%
Sep 30, 20251321.54%61,991,182-2.57%1020.93%62-25.30%4268.00%
Jun 30, 2025129-1.53%63,612,5039.51%10437.19%8110.96%26-23.53%
Mar 31, 20251320.76%62,108,0533.71%170.13%73-23.96%3478.95%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Fidelity Growth Compy Commingled Pl S3.18M3.66%4.35K
Vanguard Total Stock Mkt Idx Inv2.44M2.81%224.90K
American Funds SMALLCAP World A2.41M2.78%-1.28M
Fidelity Growth Company Fund2.27M2.61%-
iShares Russell 2000 ETF1.76M2.02%14.80K
State Street® SPDR® S&P® Biotech ETF1.20M1.38%-8.50K
Polar Capital Biotech S Inc986.26K1.14%236.43K
Fidelity Select Health Care940.00K1.08%-
T. Rowe Price Health Sciences897.04K1.03%26.46K
Fidelity Advisor Biotechnology I847.39K0.98%-

Recent Insider Transactions

DateNameRoleActivityValue
Jun 03, 2026Sloan Sheldon Chief Medical OfficerSell$624.98K
Jun 01, 2026Turtle Cameron Chief Executive OfficerSell$235.13K
Jun 01, 2026Turtle Cameron Chief Executive OfficerSell$574.50K
Jun 01, 2026Turtle Cameron Chief Executive OfficerSell$246.86K
Jun 01, 2026Burrows Scott L Chief Financial OfficerSell$125.62K

Insider Transactions Trends

DateBuySell
2026 Q2-30
2026 Q1-9
2025 Q4-4
2025 Q3-1
2025 Q2--

SYRE Ownership FAQ

Who Owns Spyre Therapeutics?

Spyre Therapeutics shareholders are primarily institutional investors at 7.08%, followed by 5.90% insiders and 87.02% retail investors. The average institutional ownership in Spyre Therapeutics's industry, Biotech Stocks , is 35.75%, which Spyre Therapeutics falls below.

Who owns the most shares of Spyre Therapeutics?

Spyre Therapeutics’s largest shareholders are Vanguard group (4.04M shares, 5.39%), Fmr (11.78M shares, 3.40%), and Blackrock funding, inc. /de (5.52M shares, 1.60%). Together, they hold 10.39% of Spyre Therapeutics’s total shares outstanding.

Does Blackrock own Spyre Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Spyre Therapeutics.

Who is Spyre Therapeutics’s biggest shareholder by percentage of total assets invested?

Fairmount funds management is Spyre Therapeutics’s biggest shareholder by percentage of total assets invested, with 14.64% of its assets in 4.02M Spyre Therapeutics shares, valued at 202.67M$.

Who is the top mutual fund holder of Spyre Therapeutics shares?

Fidelity Growth Compy Commingled Pl S is the top mutual fund holder of Spyre Therapeutics shares, with 3.66% of its total shares outstanding invested in 3.18M Spyre Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools